Erratum: A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth

Lei Wang, Jianjun Chang, Diana Varghese, Michael Dellinger, Subodh Kumar, Anne M. Best, Julio Ruiz, Richard Bruick, Samuel Penã-Llopis, Junjie Xu, David J. Babinski, Doug E. Frantz, Rolf A. Brekken, Amy M. Quinn, Anton Simeonov, Johnny Easmon & Elisabeth D. Martinez

*Nature Communications* 4:2035 doi: 10.1038/ncomms3035 (2013); Published 24 Jun 2013; Updated 22 Oct 2013

This Article contains errors in Figs 4 and 6 that were introduced during the production process. In Fig. 4d, the lane labels ‘HA-JMJD2B mut’ and ‘HA-JMJD2B’ on the western blot were inadvertently switched. In Fig. 6b,c, labels for the red and green lines were also accidentally swapped. Correct versions of both figures appear below.

**Figure 4**

![Corrected figures](image)
Figure 6

**Figure 6**

(a) Vehicle and JIB-04 groups show different median survivals (V = 28, E = 33) with a P value of 0.0007 (Log-rank) and 0.0017 (Gehan–Breslow–Wilcoxon).

(b) Normal JMJ1A and High JMJ1A groups are compared for percent survival over days post TCI.

(c) Normal UTX and High UTX groups are compared for percent survival over TTD.

(d) Diagram illustrating the effects of JIB-04e-isomer on Jumonji histone demethylases, leading to increased H3K4 methylation, upregulation of pro-apoptotic, growth inhibitory genes, and increased H3K9 methylation, downregulation of proliferative, growth-promoting genes, resulting in specific cancer cell growth inhibition and cell death.